

## **CURRICULUM VITAE**

**NAME: DAVID ARROYO**



### **IDENTIFICATION**

**Name:** David Arroyo Rueda

**Date of Birth:** 7th November 1982

**Nationality:** Spanish

**Address:** Servei de Nefrologia. Hospital Universitari Arnau de Vilanova. Avda. Rovira Roure 80, 25198 Lleida, Spain.

**e-mail address:** [drdavidarroyo@gmail.com](mailto:drdavidarroyo@gmail.com)

**Languages:** Spanish; English

### **EDUCATION**

- 2008** Medical Doctor, Facultad de Medicina, Universidad de Cantabria, Santander, Spain
- 2013** Clinical Fellowship, Kidney Transplant Program, University of California San Francisco Medical Center, U.S.A.
- 2013** Specialty in Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 2014** Master in Atherothrombotic Disease and Early Diagnosis with Non-invasive Techniques, Universidad de Lleida, Spain

### **CURRENT POSITIONS**

**Since June 2016** – Vicepresident of the Catalan Society of Nephrology.

**Since May 2016** – Board Member of the ERA EDTA *Young Nephrologist's Platform* (YNP).

**Since March 2016** – Chief of the Nephrology Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.

**Since October 2015** – Secretary of the Spanish Young Nephrologists' Platform JovSEN of the Spanish Society of Nephrology.

**Since October 2014** – Invited teacher in the Master in Atherothrombotic Disease and Early Diagnosis with Non-invasive Techniques, Universidad de Lleida, Spain.

**Since June 2014** – Invited teacher of Nephrology in CTO Medicina, Spain.

**Since September 2013** – Nephrology Specialist, Outpatient Clinic, Hospital Universitari Arnau de Vilanova, Lleida, Spain. Responsible of the Hemodialysis Unit, Hospital Comarcal del Pallars, Lleida, Spain.

Member of the Vascular and Renal Translational Research Group, IRBLleida Biomedical Research Institute, Lleida, Spain.

## **FIELDS OF INTEREST**

Acute Kidney Injury, Clinical Nephrology; Chronic Kidney Disease; Hypertension; Vascular Disease

## **AWARDS AND GRANTS**

- ERA-EDTA Young Nephrologist's Platform "Free Membership Project" Award 2014 for an article published in NDT or CKJ.

## **MEMBERSHIP IN PROFESSIONAL SOCIETIES**

- **Since 2009:** Spanish Society of Nephrology
- **Since 2011:** Spanish Society of Transplantation
- **Since 2011:** International Society of Nephrology
- **Since 2012:** European Renal Association – European Dialysis and Transplant Association
- **Since 2013:** Academy of Health and Medical Sciences of Catalonia and Balear Islands
- **Since 2013:** Catalan Society of Nephrology
- **Since 2013:** Spanish Association of Heart Image
- **Since 2015:** Spanish Society of Arteriosclerosis
- **Since 2015:** Spanish Society of Hypertension – Spanish League for the Fight against Hypertension
- **Since 2015:** American Society of Nephrology

## PUBLICATIONS

### **Book Chapters:**

- **Arroyo D**, Vinuesa SG, Goicoechea M. Profilaxis de la nefrotoxicidad por contrastes yodados. In Fernández Fresnedo G, editor. Algoritmos de Nefrología. 1st Ed. Barcelona: Grupo Editorial Nefrología - SEN; 2012. pp 16-17.
- **Arroyo D**, Vinuesa SG, Goicoechea M. Analgesia en el paciente con enfermedad renal crónica. In Fernández Fresnedo G, editor. Algoritmos de Nefrología. 1st Ed. Barcelona: Grupo Editorial Nefrología - SEN; 2012. pp 18-19.
- **Arroyo D**, Vinuesa SG, Goicoechea M. Deterioro de la función renal en el paciente con enfermedad renal crónica no candidato a terapia renal sustitutiva. In Fernández Fresnedo G, editor. Algoritmos de Nefrología. 1st Ed. Barcelona: Grupo Editorial Nefrología - SEN; 2012. pp 20-21.
- **Arroyo D**, Vinuesa SG, Goicoechea M. Dosificación de fármacos en la enfermedad renal crónica. In Fernández Fresnedo G, editor. Algoritmos de Nefrología. 1st Ed. Barcelona: Grupo Editorial Nefrología - SEN; 2012. pp 30-32.

### **Published articles:**

1. Goicoechea M, Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, **Arroyo D**, Luño J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93.  
Received: Áccesit Premio Fundación Renal Iñigo Álvarez de Toledo, 2011, in the category of Clinical Nephrology.
2. **Arroyo D**, Panizo N, Verdalles U, Vázquez-Álvarez ME, Barraca D, Quiroga B, Luño J. Acute kidney failure in the context of a TakoTsubo syndrome. Nefrología. 2011; 31(4): 493-4.
3. **Arroyo D**, Melero R, Panizo N, Goicoechea M, Rodríguez-Benítez P, García de Vinuesa S, Verde E, Luño J. Metformin-associated acute kidney injury and lactic acidosis. Int J Nephrol. 2011; 2011: 749653.
4. Panizo N, Goicoechea M, García de Vinuesa S, **Arroyo D**, Yuste C, Rincón A, Verdalles U, Ruiz-Caro C, Quiroga B, Luño J. Chronic Kidney Disease progression in patients with autosomal dominant polycystic kidney disease. Nefrología 2012; Mar 19;32(2):197-205.
5. Goicoechea M, García de Vinuesa S, **Arroyo D**, Luño J. Hyperuricemia, gout and chronic kidney disease. Nefrología Sup Ext 2012; 3(2):8-15.
6. Goicoechea M, Quiroga B, García de Vinuesa S, Verdalles U, Reque J, Panizo N, **Arroyo D**, Santos, Macías N, Luño J. Intraindividual interleukin-6 variations on the cardiovascular prognosis of patients with chronic renal disease. Ren Fail. 2012;34(8):1002-9.
7. Pascual J, Alonso A, Burgos D, Cruzado JM, Serón D; **Grupo Español de Consenso sobre disfunción renal crónica en pacientes trasplantados renales**. Chronic renal dysfunction in kidney transplant recipients. Consensus Document. Nefrología. 2012;32 Suppl 2:1-28.
8. **Arroyo D**, Panizo N, García de Vinuesa S, Goicoechea M, Verdalles U, Luño J. Hypercalcemia as a side effect of potassium binding agents. Nefrología. 2012 Sep 26;32(5):655-658.
9. **Arroyo D**. Control of anemia in the early post-transplant period. Nefrología Sup Ext. 2012;3(5):31-6. Finalist in the Contest of Clinical Cases: Kidney Patient with Anemia

(Spanish Society of Nephrology).

10. **Arroyo D**, García de Vinuesa S, Luño J. Metformin is a safe medication in mild-to-moderate chronic kidney disease. October 2012. Reply to: *Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register*. Ekström N, Schiöler L, Svensson AM et al. *BMJ Open*. 2012;2(4). pii: e001076.
11. Quiroga B, **Arroyo D**, Verde E, Eworo A, Luño J. Infective endocarditis on a percutaneous prosthetic aortic valve with associated glomerulopathy due to *Granulicatella adjacens*. *Braz J Infect Dis*. 2012 Nov; 16 (6): 601-2.
12. **Arroyo D**, Quiroga B, Panizo N, Rodríguez-Ferrero M, Macías N, Reque J, Anaya F, Luño J. High-sensitivity troponin T levels in kidney transplant recipients. *Transplant Proc*. 2012 Nov; 44(9): 2545-7.
13. Rodríguez-Ferrero M, **Arroyo D**, Panizo N, Vicario JL, Balas A, Anaya F. Monitoring of circulating antibodies in a renal transplantation population: preliminary results. *Transplant Proc*. 2012 Nov; 44(9): 2548-50.
14. Verdalles U, Vinuesa SG, Goicoechea M, Quiroga B, Reque J, Panizo N, **Arroyo D**, Luño J. Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD). *Nephrol Dial Transplant*. 2012 Dic; 27 Suppl 4:iv31-5.
15. **Arroyo D**, Domínguez P, Panizo N, Quiroga B, Calvo M, Álvarez L, Macías N, Menéndez D, Blázquez L, Galán I, Reque J. A Spanish multicentric study to evaluate the clinical activity of Nephrology fellows during in-hospital on-call shifts. *Clin Kidney J*. 2013; 6(5): 556-60.
16. Rojas L, Muñoz P, Kestler M, **Arroyo D**, Guembe M, Rodríguez-Créixems M, Verde E, Bouza E. Bloodstream infections in patients with kidney disease: risk factors for poor outcome and mortality. *J Hosp Infect*. 2013 Nov; 85(3): 196-205.
17. Quiroga B, **Arroyo D**, Goicoechea M, García de Vinuesa S, Luño J. Cardiac troponins and chronic kidney disease, what do we know? *Int J Cardiovasc Res*. 2013;2:5.
18. **Arroyo D**, Panizo N, Abad S, Vega A, Rincón A, Pérez de José A, López-Gómez JM. Intraperitoneal fluid overestimates hydration status assessment by bioimpedance spectroscopy. *Perit Dial Int*. 2015 Jan-Feb; 35(1): 85-9.
19. Pérez de José A, Verdalles Ú, Abad S, Vega A, Reque J, Panizo N, Rincón A, Yuste C, **Arroyo D**, López-Gómez JM. El síndrome metabólico se asocia con eventos cardiovasculares en hemodiálisis. *Nefrología*. 2014; 34(1): 69-75.
20. **Arroyo D**, Panizo N, Abad S, Vega A, Pérez de José A, López-Gómez JM. Efecto en el control del fósforo sérico tras la sustitución de hidróxido de aluminio por acetato cálcico/carbonato magnésico en pacientes en hemodiálisis. *Nefrología*. 2014 Mar 19; 34(2): 199-204.
21. **Arroyo D**, Chandran S, Vagefi PA, Wojciechowski D. Adjuvant Ciprofloxacin for Persistent BK Polyomavirus Infection in Kidney Transplant Recipients. *J Transplant*. 2014;2014:107459.
22. Caro J, Gutiérrez-Solís E, Rojas-Rivera J, Agraz I, Ramos N, Rabasco C, Espinosa M, Valera A, Martín M, Frutos MA, Perea L, Juárez GF, Ocaña J, **Arroyo D**, Goicoechea M, Fernández L, Oliet A, Hernández Y, Romera A, Segarra A, Praga M; for the Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. *Nephrol Dial Transplant*. 2015 Mar; 30(3): 467-74.

23. **Arroyo D**, Betriu A, Martínez-Alonso M, Vidal T, Valdivielso JM, Fernández E. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. BMC Nephrol. 2014 Oct 18; 15: 168.
24. Vega A, Quiroga B, Abad S, Aragoncillo I, **Arroyo D**, Panizo N, López-Gómez JM. Albumin leakage in online hemodiafiltration. More convective transport, more losses? Ther Apher Dial. 2015 Jun; 19(3):267-71.
25. Quiroga B, **Arroyo D**, de Arriba G. Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015; 2015: 801348.
26. Chacón A, Vilar A, **Arroyo D**, Sarró F, Craver L, Ros S, López C, Castillo A, Matías-Guiu X, Fernández-Giráldez E. Acute kidney injury secondary to very severe hypercalcemic crisis caused by primary hyperparathyroidism. Nefrología. 2015;35(2): 224-6.
27. **Arroyo D**, Panizo N, Abad S, Vega A, Rincón A, de Jose AP, López-Gómez JM. Impact of the limitations in fluid overload assessment by bioimpedance spectroscopy. Perit Dial Int. 2015 Sep-Oct; 35(5):604.
28. Gracia M, Betriu À, Martínez-Alonso M, **Arroyo D**, Abajo M, Fernández E, Valdivielso JM, NEFRONA investigators. Predictors of subclinical atheromatosis progression over 2 years in patients with different stages of CKD. Clin J Am Soc Nephrol. 2015; 11: 287-96.
29. Betriu À, Farrás C, Abajo M, Martínez-Alonso M, **Arroyo D**, Barbé F, Buti M, Lecube A, Portero M, Purroy F, Torres G, Valdivielso JM, Fernández E. Randomised intervention study to assess the prevalence of subclinical vascular disease and hidden kidney disease and its impact on morbidity and mortality: The ILERVAS project. Nefrologia 2016. [Epub ahead of print].
30. **Arroyo D**, Betriu A, Valls J, Gorrioz JL, Pallares V, Abajo M, Gracia M, Valdivielso JM, Fernández E, NEFRONA investigators. Factors influencing pathologic ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study. Nephro Dial Transplant. 2016. [Epub ahead of print].

## **OTHER ACTIVITIES**

- Over 15 invited talks and courses to doctors and nurses.
- Over 80 courses and congresses attended.
- 16 works presented as first author in 15 regional and national and 3 international congresses.
- 36 works presented as collaborator in various national and international congresses.